Q-omics provides the consensus-scored PDE4B profile across patient tissues and cancer cell-line models. PDE4B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PDE4B is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, PDE4B RNA expression shows 17,456 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, BLCA, and TGCT as cancer lineages where PDE4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE4B survival associations across molecular data types. PDE4B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE4B RNA expression–survival associations across cancer types. High PDE4B expression shows favorable associations in UVM, HNSC, SKCM, KIRC, LUAD and CHOL. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PDE4B RNA expression.
This table summarizes PDE4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE4B shows lower tumor expression in BLCA, KICH, LUSC, KIRP and LUAD and higher tumor expression in KIRC. The BLCA box plot shows higher PDE4B RNA expression in normal versus tumor tissue (log2 FC = −1.618, t-test p < 0.001).
This table shows molecular features associated with PDE4B in patient tissues and cancer cell lines. In patient samples, PDE4B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
